Table 2.
Pharmacokinetic parameters based on non-compartmental analyses [geometric mean (95% CI), range], N = 24.
| Cmax (ng/mL) | tmax (h) | t1/2 (h) | AUC24 (ng·h/mL) | AUC∞ (ng·h/mL) | CL/F (L/h) | Vz/F (L) | |
|---|---|---|---|---|---|---|---|
| LSD | |||||||
| LSD + Placebo administration | 1.9 (1.7–2.1) | 1.6 (1.4–1.9) | 3.9 (3.5–4.4) | 14 (12–16) | 14 (12–17) | 6.9 (5.8–8.3) | 39 (35–44) |
| 1.2–3.6 | 1.0–3.0 | 2.5–6.3 | 8.7–34 | 8.9–39 | 2.5–11 | 19–61 | |
| LSD+MDMA administration | 2.1 (1.9–2.3)* | 1.6 (1.4–1.9) | 5.2 (4.6–5.9)*** | 17 (15–21)** | 19 (16–22)** | 5.3 (4.5–6.4)** | 40 (36–45) |
| 1.2–3.3 | 1.0–3.5 | 2.5–8.9 | 8.1–33 | 8.3–39 | 2.6–12 | 27–77 | |
| MDMA | |||||||
| MDMA + Placebo administration | 233 (215–252) | 2.8 (2.5–3.2) | 8.3 (7.5–9.1)a | 2596 (2333–2889)a | 3083 (2713–3505)a | 32 (29–37)a | 388 (357–422)a |
| 167–306 | 1.5–5.0 | 5.0–12 | 1699–4143 | 1827–5251 | 19–55 | 274–515 | |
| LSD+MDMA administration | 208 (189–228)*** | 3.5 (3.0–4.0)** | 8.2 (7.5–9.1) | 2568 (2319–2843) | 3068 (2712–3472) | 33 (29–37) | 386 (354–422) |
| 130–318 | 2.0–6.0 | 5.6–16 | 1510–4202 | 1674–6540 | 15–60 | 237–574 |
AUC area under the plasma concentration-time curve, AUC∞ AUC from time zero to infinity, AUC24 from time 0 to 24, CL/F apparent total clearance, Cmax maximum observed plasma concentration, T1/2 plasma half-life, Tmax time to reach Cmax, 95% CI 95% confidence interval, Vz/F apparent volume of distribution.
*P < 0.05; **P < 0.01; ***P < 0.001 compared with LSD or MDMA alone, respectively (paired T-test).
aN = 23.